Improving the success rate of gluteal intramuscular injections

Pancreas. 2013 Jul;42(5):878-82. doi: 10.1097/MPA.0b013e318279d552.

Abstract

Objectives: This study aimed to improve the success rate of gluteal intramuscular (IM) injection.

Methods: The outcomes of 328 intended gluteal IM injections in 115 patients receiving depot octreotide were evaluated using computed tomography performed in routine clinical practice. Patient-, nursing-, and technique-dependent factors were correlated with successful delivery of medication. Techniques associated with successful injection were taught to center nurses.

Results: At baseline, 52% of injections were successfully delivered (66% men, 36% women; P = 0.001). Factors associated with successful delivery included nurses' frequency of injections (P = 0.008), landmarks use to select injection site (P < 0.001), quick needle insertion (P < 0.001), and use of nonsyringe hand to compress injection site (P < 0.001). Patient-related factors included male sex (P < 0.001), lower body mass index (P < 0.001), and lower skin-to-muscle depth at injection site (P < 0.001). Techniques associated with successful injections were then taught to center nurses. After instruction, the success rate increased from 52% to 75% (P = 0.001). Importantly, improvements were observed in both men (66%-75%; P = 0.43) and women (38%-75%; P < 0.001). Successful injection was associated with better control of flushing among those with carcinoid syndrome (P = 0.005).

Conclusions: Intended gluteal IM injections often are given into the subcutaneous space. Education in techniques associated with successful injections improves IM delivery rates.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Antineoplastic Agents, Hormonal / administration & dosage
  • Body Mass Index
  • Buttocks
  • Drug Delivery Systems / instrumentation
  • Drug Delivery Systems / methods*
  • Female
  • Humans
  • Injections, Intramuscular / instrumentation
  • Injections, Intramuscular / methods*
  • Male
  • Middle Aged
  • Octreotide / administration & dosage*
  • Tomography, X-Ray Computed

Substances

  • Antineoplastic Agents, Hormonal
  • Octreotide